| 1 |
Macdougall IC, Casadevall N, Locatelli F, et al. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry(PRIMS)[J]. Nephrol Dial Transplant, 2015, 30(3)：451-460.
|
| 2 |
Przybylowski P, Malyszko J, Malyszko JS. A possible role of hepcidin in the pathogenesis of anemia in heart allograft recipients[J]. Transplant Proc, 2010, 42(5)：18031807.
|
| 3 |
Xiong R, Ding LM, Liu ZJ, et al. Diagnosis and treatment strategies for anemia caused by parvovirus B19 infection after kidney transplantation [J/CD]. Pract J Organ Transplant(Electr Vers), 2021, 9(3)：249-252.
|
| 4 |
Pattison JR, Jones SE, Hodgson J, et al. Parvovirus infections and hypoplastic crisis in sickle-cell anaemia[J]. Lancet, 1981, 1(8221)：664-665.
|
| 5 |
Carraturo A, Catalani V, Ottaviani D, et al. Parvovirus B19 infection and severe anemia in renal transplant recipients[J]. Sci World J, 2012：102829.
|
| 6 |
Park JB, Kim DJ, Woo SY, et al. Clinical implications of quantitative real time-polymerase chain reaction of parvovirus B19 in kidney transplant recipients - a prospective study[J]. Transpl Int, 2009, 22(4)：455-462.
|
| 7 |
Bertoni E, Rosati A, Zanazzi M, et al. Aplastic anemia due to B19 parvovirus infection in cadaveric renal transplant recipients: an underestimated infectious disease in the immunocompromised host[J]. J Nephrol, 1997, 10(3)：152-156.
|
| 8 |
Eid AJ, Brown RA, Patel R, et al. Parvovirus B19 infection after transplantation: a review of 98 cases[J]. Clin Infect Dis, 2006, 43(1)：40-48.
|
| 9 |
Guo YM, Ishii K, Hirokawa M, et al. CpG-ODN 2006 and human parvovirus B19 genome consensus sequences selectively inhibit growth and development of erythroid progenitor cells[J]. Blood, 2010, 115(22)：4569-4579.
|
| 10 |
Pinto Natalia C, Newman C, Gomez Carlos A, et al. Parvovirus B19- induced severe anemia in heart transplant recipients: case report and review of the literature[J]. Clin Transplant, 2019, 33(4)：e13498.
|
| 11 |
Eid AJ, Ardura MI, Practice ASTIDCo. Human parvovirus B19 in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant，2019, 33 ( 9): e13535.
|
| 12 |
Rosado-Canto R, Carrillo-Pérez DL, Jiménez JV, et al. Treatment strategies and outcome of parvovirus B19 infection in kidney transplant recipients: a case series and literature review of 128 patients[J]. Rev Invest Clin, 2019, 71 (4): 265-274.
|
| 13 |
Crabol Y, Terrier B, Rozenberg F, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature[J]. Clin Infect Dis, 2013, 56(7)：968-977.
|
| 14 |
Ramage JK, Hale A, Gane E, et al. Parvovirus B19-induced red cell aplasia treated with plasmapheresis and immunoglobulin[J]. Lancet, 1994, 343 (8898)：667-668.
|
| 15 |
Gosset C, Viglietti D, Hue K, et al. How many times can parvovirus B19-related anemia recur in solid organ transplant recipients？[J]. Transpl Infect Dis, 2012, 14(5)：E64-E70.
|
| 16 |
Dao AT, Yamazaki H, Takamatsu H, et al. Cyclosporine restores hematopoietic function by compensating for decreased Tregs in patients with pure red cell aplasia and acquired aplastic anemia[J]. Ann Hematol, 2016, 95 (5)：771-781.
|
| 17 |
Baek CH, Kim H, Yang WS, et al. Risk factors and long-term outcomes of parvovirus B19 infection in kidney transplant patients[J]. Transpl Infect Dis, 2017, 19(5)： 10.1111/tid.12754.
|
| 18 |
Shiraki K, Ishibashi M, Okuno T, et al. Effects of cyclosporine, azathioprine, mizoribine, and prednisolone on replication of human cytomegalovirus[J]. Transplant Proc, 1990, 22(4)：1682-1685.
|
| 19 |
Naka K, Ikeda M, Abe K, et al. Mizoribine inhibits hepatitis C virus RNA replication: effect of combination with interferon-alpha[J]. Biochem Biophys Res Commun, 2005, 330(3)：871-879.
|
| 20 |
Kuramoto T, Daikoku T, Yoshida Y, et al. Novel anticytomegalovirus activity of immunosuppressant mizoribine and its synergism with ganciclovir[J]. J Pharmacol Exp Ther, 2010, 333(3)：816-821.
|